Sodium Hyaluronate Ophthalmic Solution, 0.18% for Treatment of Dry Eye Syndrome
Launched by ALCON RESEARCH · Jun 24, 2011
Trial Information
Current as of July 25, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Documented history of dry eyes for at least 3 months.
- • Ocular discomfort due to dry eyes.
- • Presence of corneal and conjunctival staining.
- • Other protocol-defined inclusion criteria may apply.
- Exclusion Criteria:
- • Women who are pregnant or lactating.
- • Contact lens wear within 1 week before Screening and during the study.
- • Ocular surgery (of any type, including laser surgery) or ocular trauma within the 4 months prior to Screening.
- • Punctal plugs or punctal occlusion initiated within 3 months of screening
- • Other protocol-defined exclusion criteria may apply.
About Alcon Research
Alcon Research is a leading global company dedicated to advancing eye care through innovative research and development. As a subsidiary of Novartis, Alcon focuses on the development of cutting-edge products and therapies for vision correction and eye health, including surgical, pharmaceutical, and consumer eye care solutions. With a commitment to enhancing the quality of life for patients worldwide, Alcon Research conducts rigorous clinical trials to evaluate the safety and efficacy of its products, ensuring that they meet the highest standards of care. Through collaboration with healthcare professionals and institutions, Alcon remains at the forefront of ophthalmic advancements, driving progress in the field of vision science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Michela Montecchi-Palmer, BS
Study Director
Alcon Research
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials